trial

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCTId NCT02717130
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 9 (actual)
Sponsored by Florida Atlantic University
Primary completion 2017-05-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
9 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-06-08
Primary completion
2017-05-25
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Florida Atlantic UniversityLead Sponsor
Washington University School of MedicineCollaborator
University of Missouri-ColumbiaCollaborator
University of Missouri, Kansas CityCollaborator
Burrell Behavioral HealthCollaborator

Investigators

2
John W. Newcomer, MDPrincipal Investigator
Ginger Nicol, MDPrincipal Investigator

Sites

4 total
Columbia, United StatesKansas City, United StatesSpringfield, United StatesSt Louis, United States

Facts & assertions

4 sourced
Enrollment
9
Phase
NA
Primary Completion Date
2017-05-25
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Florida Atlantic University
company
collaborator
Washington University School of Medicine
company
University of Missouri-Columbia
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
John W. Newcomer, MD
person
Ginger Nicol, MD
person